why choose us

300×250 Ad Slot

Drug FDA Status

Showing 20 of 185 result(s) (Page 2 of 19)
Drug Name: Lipfendra

Active Ingredient: enlicitide decanoate

Approval Date: 2026-07-15

Description: To reduce low-density lipoprotein cholesterol

Drug Name: Revtorpyk

Active Ingredient: gedatolisib

Approval Date: 2026-07-14

Description: In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting

Drug Name: Trutakna

Active Ingredient: atacicept-vymj

Approval Date: 2026-07-07

Description: To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression

Drug Name: Lumvoa

Active Ingredient: veligrotug-vvze

Approval Date: 2026-06-26

Description: To treat thyroid eye disease

Drug Name: Utebzi

Active Ingredient: tebipenem pivoxil

Approval Date: 2026-06-17

Description: To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options

Drug Name: Ambelvist

Active Ingredient: gadoquatrane

Approval Date: 2026-06-12

Description: To detect and visualize lesions with abnormal vascularity, in conjunction with MRI

Drug Name: Zaynich

Active Ingredient: cefepime and zidebactam

Approval Date: 2026-05-29

Description: To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms

Drug Name: Xocova

Active Ingredient: ensitrelvir

Approval Date: 2026-05-29

Description: To use as post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) following contact with an individual who has COVID-19

Drug Name: Cypsedo

Active Ingredient: cipepofol

Approval Date: 2026-05-29

Description: To induce general anesthesia in adults undergoing surgery

Drug Name: Decnupaz

Active Ingredient: pivekimab sunirine-pvzy

Approval Date: 2026-05-27

Description: To treat adults with blastic plasmacytoid dendritic cell neoplasm

300×250 Ad Slot